Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Invest ; 126(8): 3145-57, 2016 08 01.
Article in English | MEDLINE | ID: mdl-27454289

ABSTRACT

Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem. The BRCA1185delAG allele is a common inherited mutation located close to the protein translation start site that is thought to produce a shortened, nonfunctional peptide. In this study, we investigated the mechanisms that lead to PARPi and platinum resistance in the SUM1315MO2 breast cancer cell line, which harbors a hemizygous BRCA1185delAG mutation. SUM1315MO2 cells were initially sensitive to PARPi and cisplatin but readily acquired resistance. PARPi- and cisplatin-resistant clones did not harbor secondary reversion mutations; rather, PARPi and platinum resistance required increased expression of a really interesting gene (RING) domain-deficient BRCA1 protein (Rdd-BRCA1). Initiation of translation occurred downstream of the frameshift mutation, probably at the BRCA1-Met-297 codon. In contrast to full-length BRCA1, Rdd-BRCA1 did not require BRCA1-associated RING domain 1 (BARD1) interaction for stability. Functionally, Rdd-BRCA1 formed irradiation-induced foci and supported RAD51 foci formation. Ectopic overexpression of Rdd-BRCA1 promoted partial PARPi and cisplatin resistance. Furthermore, Rdd-BRCA1 protein expression was detected in recurrent carcinomas from patients who carried germline BRCA1185delAG mutations. Taken together, these results indicate that RING-deficient BRCA1 proteins are hypomorphic and capable of contributing to PARPi and platinum resistance when expressed at high levels.


Subject(s)
BRCA1 Protein/metabolism , Breast Neoplasms/drug therapy , Drug Resistance, Neoplasm , Platinum/pharmacology , Animals , Antibodies, Monoclonal/chemistry , Breast Neoplasms/metabolism , CRISPR-Cas Systems , Cell Line, Tumor , Cell Nucleus/metabolism , Cisplatin/pharmacology , Exons , Female , Germ-Line Mutation , Humans , Mice , Mice, Inbred NOD , Mutation , Neoplasm Transplantation , Poly(ADP-ribose) Polymerase Inhibitors/pharmacology , Poly(ADP-ribose) Polymerases/metabolism , Protein Domains
2.
J Virol ; 86(24): 13232-40, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23015704

ABSTRACT

Many receptors in hematopoietic cells use a common signaling pathway that relies on a highly conserved immunoreceptor tyrosine-based activation motif (ITAM), which signals through Src family tyrosine kinases. ITAM-bearing proteins are also found in many oncogenic viruses, including the mouse mammary tumor virus (MMTV) envelope (Env). We previously showed that MMTV Env expression transformed normal mammary epithelial cells and that Src kinases were important mediators in this transformation. To study how ITAM signaling affects mammary cell transformation, we utilized mammary cell lines expressing two different ITAM-containing proteins, one encoding a MMTV provirus and the other a B cell receptor fusion protein. ITAM-expressing cells were resistant to both serum starvation- and chemotherapeutic drug-induced apoptosis, whereas cells transduced with these molecules bearing ITAM mutations were indistinguishable from untransduced cells in their sensitivity to these treatments. We also found that Src kinase was activated in the MMTV-expressing cells and that MMTV-induced apoptosis resistance was completely restored by the Src inhibitor PP2. In vivo, MMTV infection delayed involution-induced apoptosis in the mouse mammary gland. Our results show that MMTV suppresses apoptosis through ITAM-mediated Src tyrosine kinase signaling. These studies could lead to the development of effective treatment of nonhematopoietic cell cancers in which ITAM-mediated signaling plays a role.


Subject(s)
Apoptosis/physiology , Mammary Glands, Animal/cytology , Mammary Tumor Virus, Mouse/physiology , Signal Transduction , Animals , Base Sequence , Cell Line , DNA Primers , Epithelial Cells/metabolism , Mammary Glands, Animal/metabolism , Mice , Mice, Inbred BALB C
3.
PLoS One ; 6(11): e27425, 2011.
Article in English | MEDLINE | ID: mdl-22087314

ABSTRACT

Non-acute transforming retroviruses like mouse mammary tumor virus (MMTV) cause cancer, at least in part, through integration near cellular genes involved in growth control, thereby de-regulating their expression. It is well-established that MMTV commonly integrates near and activates expression of members of the Wnt and Fgf pathways in mammary tumors. However, there are a significant number of tumors for which the proviral integration sites have not been identified. Here, we used high through-put screening to identify common integration sites (CISs) in MMTV-induced tumors from C3H/HeN and BALB/c mice. As expected, members of both the Wnt and Fgf families were identified in this screen. In addition, a number of novel CISs were found, including Tcf7l2, Antxr1/Tem8, and Arhgap18. We show here that expression of these three putative oncogenes in normal murine mammary gland cells altered their growth kinetics and caused their morphological transformation when grown in three dimensional cultures. Additionally, expression of Tcf7l2 and Antxr1/Tem8 sensitized cells to exogenous WNT ligand. As Tcf7l2, Antxr1/Tem8, and Arhgap18 have been associated with human breast and other cancers, these data demonstrate that MMTV-induced insertional mutation remains an important means for identifying genes involved in breast cancer.


Subject(s)
Gene Expression Regulation, Neoplastic , Genes, Neoplasm , Mammary Neoplasms, Animal/virology , Mammary Tumor Virus, Mouse/physiology , Virus Integration , Animals , Biomarkers, Tumor/genetics , Cell Proliferation , Cell Shape , Female , Hepatocyte Nuclear Factor 1-alpha , Mammary Neoplasms, Animal/genetics , Mice , Microfilament Proteins , Mutagenesis, Insertional , Receptors, Cell Surface , Receptors, Peptide/genetics , T Cell Transcription Factor 1/genetics , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...